This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Monitoring rheumatological disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Disease-modifying anti-rheumatic drugs (DMARDs) reduce tissue destruction by suppressing the auto-immune attack on the joints.

Serum acute phase proteins (ACP) are measured monthly to assess the effectiveness of DMARDs such as:

  • methotrexate
  • gold
  • sulphasalazine

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.